Literature DB >> 20007387

Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial.

A Sargent1, A Bailey, A Turner, M Almonte, C Gilham, H Baysson, J Peto, C Roberts, C Thomson, M Desai, J Mather, H Kitchener.   

Abstract

We present data on the use of the Hybrid Capture 2 (HC2) test for the detection of high-risk human papillomavirus (HR HPV) with different thresholds for positivity within a primary screening setting and as a method of triage for low-grade cytology. In the ARTISTIC population-based trial, 18,386 women were screened by cytology and for HPV. Cervical intraepithelial neoplasia lesions of grade two and higher (CIN2+ lesions) were identified for 453 women within 30 months of an abnormal baseline sample. When a relative light unit/cutoff (RLU/Co) ratio of > or = 1 was used as the threshold for considering an HC2 result positive, 15.6% of results were positive, and the proportion of CIN2+ lesions in this group was 14.7%. The relative sensitivity for CIN2+ lesion detection was 93.4%. When an RLU/Co ratio of > or = 2 was used as the threshold, there was a 2.5% reduction in positivity, with an increase in the proportion of CIN2+ lesions detected. The relative sensitivity decreased slightly, to 90.3%. Among women with low-grade cytology, HPV prevalences were 43.7% and 40.3% at RLU/Co ratios of > or = 1 and > or = 2, respectively. The proportions of CIN2+ lesions detected were 17.3% and 18.0%, with relative sensitivities of 87.7% at an RLU/Co ratio of > or = 1 and 84.2% at an RLU/Co ratio of > or = 2. At an RLU/Co ratio of > or = 1, 68.3% of HC2-positive results were confirmed by the Roche line blot assay, compared to 77.2% of those at an RLU/Co ratio of > or = 2. Fewer HC2-positive results were confirmed for 35- to 64-year-olds (50.3% at an RLU/Co ratio of > or = 1 and 63.2% at an RLU/Co ratio of > 2) than for 20- to 34-year-olds (78.7% at an RLU/Co ratio of > or = 1 and 83.7% at an RLU/Co ratio of > 2). If the HC2 test is used for routine screening as an initial test or as a method of triage for low-grade cytology, we would suggest increasing the threshold for positivity from the RLU/Co ratio of > or = 1, recommended by the manufacturer, to an RLU/Co ratio of > or = 2, since this study has shown that a beneficial balance between relative sensitivity and the proportion of CIN2+ lesions detected is achieved at this threshold.

Entities:  

Mesh:

Year:  2009        PMID: 20007387      PMCID: PMC2815647          DOI: 10.1128/JCM.00896-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Detection of high-risk HPV types by the hybrid capture 2 test.

Authors:  G Terry; L Ho; P Londesborough; J Cuzick; I Mielzynska-Lohnas; A Lorincz
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

2.  HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica.

Authors:  M Schiffman; R Herrero; A Hildesheim; M E Sherman; M Bratti; S Wacholder; M Alfaro; M Hutchinson; J Morales; M D Greenberg; A T Lorincz
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

Review 3.  The causal relation between human papillomavirus and cervical cancer.

Authors:  F X Bosch; A Lorincz; N Muñoz; C J L M Meijer; K V Shah
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

4.  Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women.

Authors:  Jean-Paul Bory; Joël Cucherousset; Marianne Lorenzato; René Gabriel; Christian Quereux; Philippe Birembaut; Christine Clavel
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

5.  Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.

Authors:  Philip E Castle; Mark Schiffman; Robert D Burk; Sholom Wacholder; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-11       Impact factor: 4.254

6.  Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools.

Authors:  S-M Kulmala; S Syrjänen; I Shabalova; N Petrovichev; V Kozachenko; J Podistov; O Ivanchenko; S Zakharenko; R Nerovjna; L Kljukina; M Branovskaja; V Grunberga; A Juschenko; P Tosi; R Santopietro; K Syrjänen
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

7.  The natural history of type-specific human papillomavirus infections in female university students.

Authors:  Harriet Richardson; Gail Kelsall; Pierre Tellier; Hélène Voyer; Michal Abrahamowicz; Alex Ferenczy; François Coutlée; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-06       Impact factor: 4.254

8.  Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Authors:  Shalini L Kulasingam; James P Hughes; Nancy B Kiviat; Constance Mao; Noel S Weiss; Jane M Kuypers; Laura A Koutsky
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

9.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

Authors:  Henry C Kitchener; Maribel Almonte; Claire Thomson; Paula Wheeler; Alexandra Sargent; Boyka Stoykova; Clare Gilham; Helene Baysson; Christopher Roberts; Robin Dowie; Mina Desai; Jean Mather; Andrew Bailey; Andrew Turner; Sue Moss; Julian Peto
Journal:  Lancet Oncol       Date:  2009-06-17       Impact factor: 41.316

10.  Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

Authors:  C Clavel; M Masure; J P Bory; I Putaud; C Mangeonjean; M Lorenzato; P Nazeyrollas; R Gabriel; C Quereux; P Birembaut
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

View more
  18 in total

1.  Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China.

Authors:  Fang-Hui Zhao; Margaret Jane Lin; Feng Chen; Shang-Ying Hu; Rong Zhang; Jerome L Belinson; John W Sellors; Silvia Franceschi; You-Lin Qiao; Philip E Castle
Journal:  Lancet Oncol       Date:  2010-11-11       Impact factor: 41.316

2.  Human papillomavirus viral load expressed as relative light units (RLU) correlates with the presence and grade of preneoplastic lesions of the uterine cervix in atypical squamous cells of undetermined significance (ASCUS) cytology.

Authors:  M Origoni; G Carminati; S Rolla; M Clementi; M Sideri; M T Sandri; M Candiani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-01       Impact factor: 3.267

3.  Optimal positive cutoff points for careHPV testing of clinician- and self-collected specimens in primary cervical cancer screening: an analysis from rural China.

Authors:  Le-Ni Kang; Jose Jeronimo; You-Lin Qiao; Fang-Hui Zhao; Wen Chen; Melissa Valdez; Xun Zhang; Pooja Bansil; Proma Paul; Ping Bai; Roger Peck; Jing Li; Feng Chen; Mark H Stoler; Philip E Castle
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

4.  Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with Amplicor HPV and Hybrid Capture 2 assays for detection of high-grade lesions of the uterine cervix.

Authors:  Simon Dufresne; Philippe Sauthier; Marie-Hélène Mayrand; Patrick Petignat; Diane Provencher; Pierre Drouin; Philippe Gauthier; Marie-Josée Dupuis; Bertrand Michon; Stéphan Ouellet; Rachid Hadjeres; Alex Ferenczy; Eduardo L Franco; François Coutlée
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

5.  Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.

Authors:  Mario Poljak; Anja Ostrbenk; Katja Seme; Veronika Ucakar; Peter Hillemanns; Eda Vrtacnik Bokal; Nina Jancar; Irena Klavs
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

6.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test.

Authors:  D C Rijkaart; V M H Coupe; F J van Kemenade; D A M Heideman; A T Hesselink; W Verweij; L Rozendaal; R H Verheijen; P J Snijders; J Berkhof; C J L M Meijer
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

7.  Hybrid capture 2 test results after an initial equivocal RLU/CO value are dependent on age.

Authors:  Camille T Elkins; Christiaan E de Vries; Julie Stephens; Adrian A Suarez
Journal:  Am J Clin Pathol       Date:  2013-05       Impact factor: 2.493

8.  The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.

Authors:  Emma J Crosbie; Andrew Bailey; Alex Sargent; Clare Gilham; Julian Peto; Henry C Kitchener
Journal:  J Clin Microbiol       Date:  2015-09-02       Impact factor: 5.948

9.  Suppression of miR-93-5p inhibits high-risk HPV-positive cervical cancer progression via targeting of BTG3.

Authors:  Jie Li; Zhao-Ping Chu; Hua Han; Yuan Zhang; Fei Tian; Jun-Qin Zhang; Xiang-Hua Huang
Journal:  Hum Cell       Date:  2019-01-28       Impact factor: 4.174

10.  Sensitive HPV genotyping based on the flow-through hybridization and gene chip.

Authors:  Pingping Tao; Weiping Zheng; Yungen Wang; Mei-Lu Bian
Journal:  J Biomed Biotechnol       Date:  2012-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.